



Axxam enters into Drug Discovery Collaboration with Vivozon for CNS Indications

Milan, Italy – 12 May 2020 – Axxam S.p.A. announces a collaboration with Vivozon Inc. with the aim to support Vivozon in the development of innovative small molecule drugs for the treatment of patients with unmet CNS medical needs.

Thanks to its expertise in early phase discovery biology, Axxam began the collaboration with Vivozon by providing access to a panel of cell-based assays to test Vivozon's compounds on targets of interest, thereby supporting Vivozon's scientists in the hit-to-lead program and drug discovery research.

Dr. Stefan Lohmer, Co-founder & Chief Executive Officer of Axxam, commented, "We are extremely pleased with the collaboration we have established with Vivozon over the past few years and we are looking forward to continuing and expanding it in the future. We are excited that Vivozon is our first client based in the Republic of Korea, which is consistently ranked as one of the top innovative countries in the world".

Dr. Doo Lee, Co-founder & Chief Executive Officer of Vivozon, added, "We are grateful to have Axxam as our partner, and greatly appreciate their support and commitment in helping us make progress with the discovery of innovative CNS drugs by providing top-quality services. We believe that more Korean companies will collaborate with Axxam in the drug discovery field".

About Vivozon Inc.

Vivozon Inc. is specialized in the discovery, development and commercialization of the small molecule drugs for the treatment of patients with the unmet CNS medical needs by applying the innovative approach to rapidly identify the lead compounds using its unique ex vivo/phenotypic screening technology. The company is focused on the development of the safe non-opioid-next-generation pain killer for the patients suffering from operations, neuropathic pain, cancer pain, etc. Vivozon's lead drug candidate, VVZ-149, is currently in the phase 3 clinical trials (USA) for the treatment of post-operative pain. Currently, two back-up programs of second and third generation of VVZ-149 are active with many hits and new lead molecules. After the 10-years of service at the global big pharma in the U.S. as a research scientist in the department of neuroscience, Dr. Doo Lee, along with Professor Kyung-Woon Jung of USC (Department of Chemistry), CA, USA, has founded Vivozon in 2008. The company is actively running the drug discovery programs for the CNS indications based upon the ex vivo/phenotypic screening technology developed by Dr. Lee. For more information, please visit www.vivozon.com



About Axxam SpA

Axxam SpA is a privately owned iPRO (innovative Partner Research Organization) and discovery company located at the Science Park OpenZone in Bresso (Milan, Italy). The Company is a leading provider of discovery services for the entire life sciences industries as: pharmaceutical, crop protection, animal health, cosmetics and nutrition. Axxam has a strong expertise across a broad range of discovery disciplines and innovative technologies, including: assay development, compound management, HTS, hit identification and hit validation. Axxam is also engaged in developing novel innovative therapies for diseases with a high unmet medical need. For more information, please visit www.axxam.com.